Breaking News
Investing Pro 0

Big Pharma vs Big Pharma in court battles over biosimilar drugs

Stock Markets Oct 02, 2016 05:20AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. File photo of an Amgen sign at the company's office in South San Francisco
 
MRK
+1.10%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AMGN
-0.23%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BIIB
+2.40%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
-0.33%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
-0.67%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By John Miller

ZURICH (Reuters) - The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals' complex biological medicines.

These drugmakers are now increasingly straddling both sides of the courtroom, too, protecting their high-price products from biosimilars - biopharmaceutical drugs with the treatment properties of medicines they seek to mimic - while simultaneously challenging rivals' patent claims.

Biologics, manufactured in living cells, then extracted and purified, are more complex than traditional medicines and cannot be copied with precision, and so their knock-off versions are called biosimilars instead of generics.

The allure of biosimilars is clear, with insurers and other payers counting on the steep discounts. U.S. pharmacy benefit managers are already trimming brand-name drugs from their rosters.

With Novartis Chief Executive Joe Jimenez predicting biosimilar discounts of up to 75 percent, in part based on developments in Europe, makers of innovative drugs are fighting tooth and nail to protect their higher-priced products for as long as possible. [

For instance, AbbVie has sued in Delaware claiming patent protection for its arthritis drug Humira, the world's best-selling prescription medicine, until at least 2022 as it seeks to delay an Amgen (NASDAQ:AMGN) replica that won U.S. approval last week.

Meanwhile, Amgen has gone to another U.S. federal court seeking to protect its own arthritis medicine, Enbrel, from a Novartis biosimilar until 2029.

With lawsuits pitting Big Pharma against Big Pharma piling up, lawyers said the legal landscape has gotten a lot more complex.

"One of the biggest surprises has been the number of innovator biopharma companies, like Amgen, now developing biosimilars to compete with the products of other innovator companies," said Don Ware, an expert on biosimilars at U.S. law firm Foley Hoag in Boston. 

“This creates conflicts for law firms like ours, because suddenly the clients we advise are adverse to each other," Ware said. "And it makes it hard for the companies to retain top outside counsel without having to give them conflict waivers.”

Sanofi, Merck (NYSE:MRK), Eli Lilly, Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and Biogen (NASDAQ:BIIB) are also embroiled in lawsuits over biosimilars.

NOT BITTER ENEMIES

Even so, some analysts say the lawsuits are business as usual and are unlikely to spill over into other areas, including research partnerships.

Novartis and Amgen may be at each other's throats in court over the Swiss drugmaker's Enbrel copy, but the two are still cooperating on a drug for migraines.

"It's not like these companies are bitter enemies," Zuercher Kantonalbank analyst Michael Nawrath said. "These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their blockbusters."

Conflicts pitting big drugmakers against each other may have been inevitable after Europe in 2006 and the United States in 2010 created separate biosimilar approval rules.

After all, Big Pharma's financial clout and expertise made large, sophisticated drugmakers the natural candidates to manufacture complex biosimilar copies that cost hundreds of millions to bring to market, far more than for generic off-patent copies of simpler, small molecule drugs.

Some smaller companies and generics makers have jettisoned biosimilar programs after originally underestimating hurdles to entry, Richard Francis, head of Novartis's Sandoz division that makes biosimilars, said earlier this year.

Just this week, Shire abandoned two biosimilar candidate drugs that accompanied its Baxalta takeover, copies of Amgen's Enbrel and AbbVie's Humira, to focus on rare diseases.

"The realization of what it's going to take to stay in this market and be successful has led to a change in the landscape and the players in it," Francis said.

Big Pharma vs Big Pharma in court battles over biosimilar drugs
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email